BIOMAT Database Logo BIOMAT Database Logo

Induction of differentiation of human myeloid leukemia cells by novel synthetic neurotrophic pyrimidine derivatives. 2001

Y Honma, and Y Ishii, and T Kasukabe, and J Okabe-Kado, and Y Yamamoto-Yamaguchi, and T Kakegawa, and A Awaya
Saitama Cancer Center Research Institute, Ina, Saitama, Japan. honma@cancer-c.pref.saitama.jp

OBJECTIVE Some pyrimidine analogues have been found to induce differentiation of several human myeloid leukemia cells. Newly synthesized heterocyclic pyrimidine derivatives promote neurite outgrowth and survival in neuronal cell lines. In this study, the growth-inhibiting and differentiation-inducing effects of these pyrimidine derivatives on human myeloid leukemia cells were examined. METHODS Several myeloid leukemia cells were cultured with novel heterocyclic pyrimidine derivatives. Cell differentiation was determined by nitroblue tetrazolium-reducing activity, morphologic changes, expression of CD11b, lysozyme activity, and hemoglobin production. RESULTS MS-430 (2-piperidino-5,6-dihydro-7-methyl-6-oxo (7H) pyrrolo [2,3-d] pyrimidine maleate) effectively induced HL-60 cells into mature granulocytes. MS-430 activated the mitogen-activated protein kinase (MAPK) of the cells before causing granulocytic differentiation. MAPK activation was necessary for MS-430-induced differentiation, because PD98059, an inhibitor of MAPK kinase, suppressed the differentiation induced by MS-430. MS-430 also induced monocytic differentiation of THP-1, P39/Tsu, and P31/Fuj leukemia cells, but did not affect erythroid differentiation of K562 or HEL cells. CONCLUSIONS MS-430 potently induces differentiation of some myelomonocytic leukemia cells. This novel synthesized pyrimidine compound shows promise as a therapeutic agent for treatment of leukemia and as a neurotrophic drug.

UI MeSH Term Description Entries
D007951 Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. Granulocytic Leukemia,Leukemia, Granulocytic,Leukemia, Myelocytic,Leukemia, Myelogenous,Myelocytic Leukemia,Myelogenous Leukemia,Myeloid Leukemia,Leukemia, Monocytic, Chronic,Monocytic Leukemia, Chronic,Chronic Monocytic Leukemia,Chronic Monocytic Leukemias,Granulocytic Leukemias,Leukemia, Chronic Monocytic,Leukemias, Chronic Monocytic,Leukemias, Granulocytic,Leukemias, Myelocytic,Leukemias, Myelogenous,Leukemias, Myeloid,Monocytic Leukemias, Chronic,Myelocytic Leukemias,Myelogenous Leukemias,Myeloid Leukemias
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D009580 Nitroblue Tetrazolium Colorless to yellow dye that is reducible to blue or black formazan crystals by certain cells; formerly used to distinguish between nonbacterial and bacterial diseases, the latter causing neutrophils to reduce the dye; used to confirm diagnosis of chronic granulomatous disease. Nitro-BT,Nitrotetrazolium Blue,Tetrazolium Nitroblue,Blue, Nitrotetrazolium,Nitroblue, Tetrazolium,Tetrazolium, Nitroblue
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D002117 Calcitriol The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. 1 alpha,25-Dihydroxycholecalciferol,1 alpha,25-Dihydroxyvitamin D3,1, 25-(OH)2D3,1,25(OH)2D3,1,25-Dihydroxycholecalciferol,1,25-Dihydroxyvitamin D3,1 alpha, 25-dihydroxy-20-epi-Vitamin D3,1,25(OH)2-20epi-D3,1,25-dihydroxy-20-epi-Vitamin D3,20-epi-1alpha,25-dihydroxycholecaliferol,Bocatriol,Calcijex,Calcitriol KyraMed,Calcitriol-Nefro,Decostriol,MC-1288,MC1288,Osteotriol,Renatriol,Rocaltrol,Silkis,Sitriol,Soltriol,Tirocal,1 alpha,25 Dihydroxyvitamin D3,1,25 Dihydroxycholecalciferol,1,25 Dihydroxyvitamin D3,1,25 dihydroxy 20 epi Vitamin D3,Calcitriol Nefro,D3, 1 alpha,25-Dihydroxyvitamin,D3, 1,25-Dihydroxyvitamin,D3, 1,25-dihydroxy-20-epi-Vitamin,KyraMed, Calcitriol,MC 1288
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D004915 Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood. Di Guglielmo's Disease,Erythremic Myelosis,Erythroblastic Leukemia, Acute,Erythroleukemia,Leukemia, Myeloid, Acute, M6,Myeloid Leukemia, Acute, M6,Di Guglielmo Disease,Acute Erythroblastic Leukemia,Acute Erythroblastic Leukemias,Di Guglielmos Disease,Disease, Di Guglielmo,Disease, Di Guglielmo's,Erythremic Myeloses,Erythroblastic Leukemias, Acute,Erythroleukemias,Leukemia, Acute Erythroblastic,Leukemias, Acute Erythroblastic,Myeloses, Erythremic,Myelosis, Erythremic

Related Publications

Y Honma, and Y Ishii, and T Kasukabe, and J Okabe-Kado, and Y Yamamoto-Yamaguchi, and T Kakegawa, and A Awaya
Induction of differentiation of human myeloid leukemia HL-60 cells by novel pyrimidine nucleoside analogs.
August 1991, Biochimica et biophysica acta,
Y Honma, and Y Ishii, and T Kasukabe, and J Okabe-Kado, and Y Yamamoto-Yamaguchi, and T Kakegawa, and A Awaya
Inhibition of pyrimidine biosynthesis by strobilurin derivatives induces differentiation of acute myeloid leukemia cells.
May 2022, Leukemia & lymphoma,
Y Honma, and Y Ishii, and T Kasukabe, and J Okabe-Kado, and Y Yamamoto-Yamaguchi, and T Kakegawa, and A Awaya
Inhibition of proliferation and induction of differentiation of human myeloid leukemia cells by novel nucleoside analogs.
January 1988, Anticancer research,
Y Honma, and Y Ishii, and T Kasukabe, and J Okabe-Kado, and Y Yamamoto-Yamaguchi, and T Kakegawa, and A Awaya
Induction of differentiation of human myeloid leukemia HL-60 cells by novel nonphosphorus alkyl ether lipids.
December 1991, Lipids,
Y Honma, and Y Ishii, and T Kasukabe, and J Okabe-Kado, and Y Yamamoto-Yamaguchi, and T Kakegawa, and A Awaya
Induction of differentiation of human and mouse myeloid leukemia cells by camptothecin.
January 1990, Biochemical and biophysical research communications,
Y Honma, and Y Ishii, and T Kasukabe, and J Okabe-Kado, and Y Yamamoto-Yamaguchi, and T Kakegawa, and A Awaya
Induction of differentiation of human myeloid leukemia cells by inhibitors of DNA synthesis.
October 1982, Experimental hematology,
Y Honma, and Y Ishii, and T Kasukabe, and J Okabe-Kado, and Y Yamamoto-Yamaguchi, and T Kakegawa, and A Awaya
Induction of differentiation in human myeloid leukemia cells with cytosine arabinoside.
January 1986, Leukemia research,
Y Honma, and Y Ishii, and T Kasukabe, and J Okabe-Kado, and Y Yamamoto-Yamaguchi, and T Kakegawa, and A Awaya
Induction of differentiation of cultured human and mouse myeloid leukemia cells by alkyl-lysophospholipids.
August 1981, Cancer research,
Y Honma, and Y Ishii, and T Kasukabe, and J Okabe-Kado, and Y Yamamoto-Yamaguchi, and T Kakegawa, and A Awaya
Induction of differentiation of human and murine myeloid leukemia cells in culture by tunicamycin.
January 1980, Proceedings of the National Academy of Sciences of the United States of America,
Y Honma, and Y Ishii, and T Kasukabe, and J Okabe-Kado, and Y Yamamoto-Yamaguchi, and T Kakegawa, and A Awaya
Induction of gp130 and LIF by differentiation inducers in human myeloid leukemia K562 cells.
December 1999, Leukemia research,
Copied contents to your clipboard!